Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-25-283441·Ikarian Capital, LLC
Schedule 13G ownership disclosure
Relmada Therapeutics Inc
Common Stock, par value $0.001 par value per share · CUSIP: 75955J402
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Ikarian Capital, LLC
Shares: 3,543,359 · Class: 4.8%
- Neil Shahrestani
Shares: 3,543,359 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-283441
- Form type
- SCHEDULE 13G
- Filer
- Ikarian Capital, LLC
- CIK
- CIK 1778253
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership